Background: Research has shown that medications, especially opioid agonist treatments, are an effective way to treat opioid use disorder (OUD); however, negative attitudes held by health professionals contribute to their underutilization. Methods: A 23-year review of studies that examined health professionals’ attitudes toward medications for OUD (MOUD) was conducted to describe the current state of knowledge and to inform future research and interventions. Results: Studies examined attitudes toward the use of methadone, buprenorphine, and naltrexone among various types of health professionals: prescribers, non-prescribing clinicians, pharmacists, and administrators. The characteristics and findings of the included studies were reviewed and synthesized. Findings indicate that attitudes toward MOUD affect access and utilization by influencing prescribing practices, referrals, and adoption within programs. Exposure, knowledge, and treatment orientation were found to be important factors related to attitudes toward MOUD across multiple studies of various types of health professionals. Conclusions: To increase access and utilization, continued efforts are needed to increase positive attitudes toward MOUD among various types of health professionals. Findings indicate that interventions should seek to increase knowledge about MOUD and foster interprofessional communication related to MOUD, especially between prescribers and behavioral health providers.
ManchikantiL, HelmS, FellowsBOpioid epidemic in the United States. Pain Physician. 2012;15(3):ES9–ES38.
2.
Substance Abuse and Mental Health Services Administration. Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. North Bethesda, MD: Center for Behavioral Health Statistics and Quality; 2019.
3.
International Narcotics Control Board. Narcotic Drugs: Estimated Word Requirements for 2018, Statistics for 2016. New York, NY: United Nations; 2017.
4.
FlorenceCS, ZhouC, LuoF, XuL.The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–906.
5.
PollackHA.So prescription opioid disorders are a $78.5 billion problem. Med Care. 2016;54(10):899–900.
6.
DegenhardtL, BucelloC, MathersBMortality among regular or dependent users of heroin and other opioids: a systematic review and meta‐analysis of cohort studies. Addiction. 2011;106(1):32–51.
7.
SordoL, BarrioG, BravoMJMortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
8.
VolkowND, FriedenTR, HydePS, ChaSS.Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
9.
BaserO, ChalkM, FiellinDA, GastfriendDR.Cost and utilization outcomes of opioid-dependence treatments. Am J Managed Care. 2011;17(8):S235.
10.
Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. North Bethesda, MD: SAMHSA; 2005.
11.
BartG.Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–225.
12.
FiellinDA, SchottenfeldRS, CutterCJ, MooreBA, BarryDT, O'ConnorPG.Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947–1954.
13.
SeesKL, DelucchiKL, MassonCMethadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–1310.
14.
RettigRA, YarmolonskyA.Federal Regulation of Methadone Treatment. Washington, DC: National Academy; 1995.
SyedYY, KeatingGM.Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs. 2013;27(10):851–861.
19.
LeeJD, NunesEV, NovoPJrComparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. The Lancet. 2018;391(10118):309–318.
20.
Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. North Bethesda, MD: SAMHSA; 2015.
21.
AmatoL, MinozziS, DavoliM, VecchiS, FerriM, MayetS.Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2004;4:CD004147.
22.
BrownA.A systematic review of psychosocial interventions in treatment of opioid addiction. J Soc Work Pract Addict. 2018;18(3):249–269.
23.
WeissRD, PotterJS, FiellinDAAdjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–1246.
24.
VeilleuxJC, ColvinPJ, AndersonJ, YorkC, HeinzAJ.A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155–166.
25.
MartinSA, ChiodoLM, BosseJD, WilsonA.The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
26.
CarrollKM, WeissRD.The role of behavioral interventions in buprenorphine maintenance treatment: a review. AJP. 2017;174(8):738–747.
27.
JonesCM, CampopianoM, BaldwinG, McCance-KatzE.National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
28.
WuL-T, ZhuH, SwartzMS.Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
29.
KolodnyA, CourtwrightDT, HwangCSThe prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559–574.
30.
MaddenLM, FarnumSO, EggertKFAn investigation of an open‐access model for scaling up methadone maintenance treatment. Addiction. 2018;113(8):1450–1458.
31.
MurthyVH.Ending the opioid epidemic—a call to action. N Engl J Med. 2016;375(25):2413–2415.
32.
CarrieriMP, AmassL, LucasGM, VlahovD, WodakA, WoodyGE.Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(4):S197–S215.
33.
SchwartzRP, GryczynskiJ, O'GradyKEOpioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–922.
34.
JonesEB.Medication‐assisted opioid treatment prescribers in federally qualified health centers: capacity lags in rural areas. J Rural Health. 2018;34(1):14–22.
35.
SteinBD, SorberoM, DickAW, PaculaRL, BurnsRM, GordonAJ.Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.
36.
WakemanSE.Using science to battle stigma in addressing the opioid epidemic: opioid agonist therapy saves lives. Am J Med. 2016;129(5):455–456.
37.
WakemanSE, RichJD.Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–333.
38.
OlsenY, SharfsteinJM.Confronting the stigma of opioid use disorder-and its treatment. JAMA. 2014;311(14):1393–1394.
39.
WakemanSE, RichJD.Barriers to post-acute care for patients on opioid agonist therapy; An example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17–19.
40.
MagrathSM.Medication Assisted Treatment and the Three Legged Stool: Medical Providers, Chemical Dependency Professionals, and Clients [dissertation]. Culver City, CA: Antioch University; 2016.
41.
TrevorE.Attitudes and Beliefs Toward Methadone Maintenance Treatment Among General Practitioners and Nurses [dissertation]. San Francisco, CA: California Institute of Integral Studies; 2011.
42.
OlivaEM, MaiselNC, GordonAJ, HarrisAH.Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374–381.
43.
WeberEM.Failure of physicians to prescribe pharmacotherapies for addiction: regulatory restrictions and physician resistance. J Health Care Law & Policy. 2010;13:49.
44.
HadlandSE, ParkTW, BagleySM.Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018;13(1):15.
45.
CaplehornJRM, HartelDM, IrwigL.Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. Subst Use Misuse. 1997;32(4):399–413.
TuchmanE, BonuckK, TommaselloA, DruckerE.Office based methadone treatment: a role for community pharmacists. Addict Disord Treat. 2003;2(3):91–96.
49.
WryobeckJM.The Relative Importance of Client Characteristics in Recommending a Harm Reduction Treatment Strategy: A Policy Capturing Study of Psychologists [dissertation]. Bowling Green, OH: Bowling Green State University; 2003.
50.
GoddardP.Changing attitudes towards harm reduction among treatment professionals: a report from the American Midwest. Int J Drug Policy. 2003;14(3):257–260.
51.
RosenbergH, PhillipsKT.Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies. Psychol Addict Behav. 2003;17(3):203–210.
52.
McCartyD, RieckmannT, GreenC, GallonS, KnudsenJ.Training rural practitioners to use buprenorphine: using the change book to facilitate technology transfer. J Subst Abuse Treat. 2004;26(3):203–208.
53.
KnudsenHK, DucharmeLJ, RomanPM, LinkT.Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29(2):95–106.
54.
MerrillJO, JacksonTR, SchulmanBAMethadone medical maintenance in primary care: an implementation evaluation. J Gen Intern Med. 2005;20(4):344–349.
55.
TuchmanE, GregoryC, SimsonJM, DruckerE.Office-based opioid treatment (OBOT): practitioner's knowledge, attitudes, and expectations in New Mexico. Addict Disorders Treat. 2005;4(1):11–19.
56.
ArfkenCL, AgiusE, DicksonMW, AndersonHL, HegedusAM.Clinicians’ beliefs and awareness of substance abuse treatments in research-and nonresearch-affiliated programs. J Drug Issues. 2005;35(3):547–558.
57.
McMillanGP, LaphamSC.Staff perspectives on methadone maintenance therapy (MMT) in a large southwestern jail. Addict Res Theory. 2005;13(1):53–63.
58.
RaischDW, FudalaPJ, SaxonAJPharmacists’ and technicians’ perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc. 2005;45(1):23–32.
59.
RichJD, BoutwellAE, ShieldDCAttitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82(3):411–419.
60.
TurnerBJ, LaineC, LinYT, LynchK.Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–1776.
61.
CunninghamCO, SohlerNL, McCoyK, KuninsHV.Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Family Medicine Kansas City. 2006;38(5):336.
62.
EvansJS.Assessing and Comparing Attitudes toward Addiction and Methadone Treatment [dissertation]. Athens, OH: Ohio University; 2006.
63.
Havranek JE, Stewart JR. Rehabilitation counselors’ attitudes toward harm reduction measures. Journal of Applied Rehabilitation Counseling. 2006;37(1):38–44.
64.
AndrewsS, SorensenJL, GuydishJ, DelucchiK, GreenbergB.Knowledge and attitudes about methadone maintenance among staff working in a therapeutic community. J Maintenance Addict. 2005;3(1):47–59.
65.
KissinW, McLeodC, SonnefeldJ, StantonA.Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91–103.
66.
CunninghamCO, KuninsHV, RooseRJ, ElamRT, SohlerNL.Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–1329.
67.
FullerBE, RieckmannT, NunesEVOrganizational readiness for change and opinions toward treatment innovations. J Subst Abuse Treat. 2007;33(2):183–192.
68.
KnudsenHK, DucharmeLJ, RomanPM.The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007;87(2–3):164–174.
69.
McCartyD, FullerBE, ArfkenCDirect care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv. 2007;58(2):181–190.
70.
RieckmannT, DaleyM, FullerBE, ThomasCP, McCartyD.Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007;32(2):207–215.
71.
VarraAA, HayesSC.Assessing referrals for pharmacotherapy: a comparison of therapist and client report. J Subst Abuse Treat. 2007;32(4):411–413.
72.
RooseRJ, KuninsHV, SohlerNL, ElamRT, CunninghamCO.Nurse practitioner and physician assistant interest in prescribing buprenorphine. J Subst Abuse Treat. 2008;34(4):456–459.
73.
ThomasCP, ReifS, HaqS, WallackSS, HoytA, RitterGA.Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatr Serv. 2008;59(8):909–916.
74.
VarraAA, HayesSC, RogetN, FisherG.A randomized control trial examining the effect of acceptance and commitment training on clinician willingness to use evidence-based pharmacotherapy. J Consult Clin Psychol. 2008;76(3):449–458.
75.
HerbeckDM, HserYI, TeruyaC.Empirically supported substance abuse treatment approaches: a survey of treatment providers’ perspectives and practices. Addict Behav. 2008;33(5):699–712.
76.
FitzgeraldJ, McCartyD.Understanding attitudes toward use of medication in substance abuse treatment: a multilevel approach. Psychol Serv. 2009;6(1):74–84.
77.
NetherlandJ, BotskoM, EganJEFactors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244–251.
78.
AlbrightJ, CiaverelliR, EssexA, TkaczJ, RuetschC.Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. J Addict Med. 2010;4(4):197–203.
79.
AbrahamAJ, RieckmannT, McNultyT, KovasAE, RomanPM.Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav. 2011;36(6):576–583.
80.
AgnewCJ.Buprenorphine as an Efficacious Treatment for Opioid Dependency? A Survey of Counselors Attitudes [dissertation]. Athens, OH: Ohio University; 2011.
81.
RieckmannTR, KovasAE, McFarlandBH, AbrahamAJ.A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. J Subst Abuse Treat. 2011;41(4):374–385.
82.
BrideBE, AbrahamAJ, KintzleS, RomanPM.Social workers’ knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. Soc Work Health Care. 2013;52(1):43–58.
83.
Schuman-OlivierZ, ConneryH, GriffinMLClinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013;22(6):574–580.
84.
HutchinsonE, CatlinM, AndrillaCHA, BaldwinLM, RosenblattRA.Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–133.
85.
RieckmannTR, AbrahamAJ, KovasAE, McFarlandBH, RomanPM.Impact of research network participation on the adoption of buprenorphine for substance abuse treatment. Addict Behav. 2014;39(5):889–896.
86.
RobertoAJ, ShaferMS, MarmoJ.Predicting substance-abuse treatment providers’ communication with clients about medication assisted treatment: a test of the theories of reasoned action and planned behavior. J Subst Abuse Treat. 2014;47(5):307–313.
87.
SuzukiJ, ConneryHS, EllisonTV, RennerJA.Preliminary survey of office‐based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency. Am J Addict. 2014;23(6):618–622.
88.
DeFlavioJR, RolinSA, NordstromBR, KazalLA.Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15(1):3019.
89.
FriedmannPD, WilsonD, KnudsenHKEffect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015;50:50–58.
90.
AletrarisL, EdmondMB, PainoM, FieldsD, RomanPM.Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Subst Abus. 2016;37(1):47–53.
91.
EstreetA, ArchibaldP, TirmaziMT, GoodmanS, CudjoeT.Exploring social work student education: the effect of a harm reduction curriculum on student knowledge and attitudes regarding opioid use disorders. Subst Abus. 2017;38(4):369–375.
KermackA, FlanneryM, TofighiB, McNeelyJ, LeeJD.Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1–6.
94.
RieckmannT, MooreL, CroyC, AaronsGA, NovinsDK.National overview of medication-assisted treatment for American Indians and Alaska natives with substance use disorders. Psychiatr Serv. 2017;68(11):1136–1143.
95.
JamesJR, GordonLM, KleinJW, MerrillJO, TsuiJI.Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic. Subst Abuse. 2019;40(1):11–13.
96.
JonesCM, McCance‐KatzEF.Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471–482.
97.
PytellJD, BureshME, GraddyR.Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract. 2019;14(1):1–7.
98.
ImDD, CharyA, CondellaALEmergency department clinicians’ attitudes toward opioid use disorder and emergency department-initiated buprenorphine treatment: a mixed-methods study. West J Emerg Med. 2020;21(2):261–271.
99.
GuerreroE, OberAJ, HowardDLOrganizational factors associated with practitioners’ support for treatment of opioid use disorder in the emergency department. Addict Behav. 2020;102:106197.
100.
CalcaterraSL, BinswangerIA, EdelmanEJ, McNairBK, WakemanSE, O'ConnorPG.The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: a survey of hospitalist physicians. Substance Abuse. 2020;1–9.
101.
McGintyEE, StoneEM, Kennedy-HendricksA, BachhuberMA, BarryCL.Medication for opioid use disorder: a national survey of primary care physicians. Ann Intern Med. 2020;173(2):160–162.
102.
HaffajeeRL, Andraka-ChristouB, AttermannJ, CupitoA, BucheJ, BeckAJ.A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prevent Policy. 2020;15(69):1–13.
103.
JonesJ, TierneyM, JacobsG, ChienSY, MallishamS.Empowering psychiatric mental health nurse practitioners to expand treatment opportunities for veterans with opioid use disorder. J Addict Nurs. 2020;31(4):261–268.
104.
Kennedy-HendricksA, BarryCL, StoneE, BachhuberMA, McGintyEE.Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians. Drug Alcohol Depend. 2020;216:108217.
105.
SchultzJMO.Acceptance of Primary Care Providers Acquiring Buprenorphine Waivers for Opioid Use Disorder Population in Rural Upstate New York [dissertation]. Binghamton, NY: State University of New York at Binghamton; 2020.
106.
BrackettCD, DuncanM, WagnerJF, FinebergL, KraftS.Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. Subst Abuse. 2021;1–5.
107.
LienIRC, SeatonR, SzpytmanAEight-hour medication-assisted treatment waiver training for opioid use disorder: integration into medical school curriculum. Medical Education Online. 2021;26(1):1847755–1847754.
108.
OrosSM, ChristonLM, BarthKS, BeriniCR, PadgettBL, DiazVA.Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina. Int J Psychiatry Med. 2021;56(1):14–39.
109.
MortSC, DiazSR, BeverlyEA.Using contact-based education to destigmatize opioid use disorder among medical students. Teach Learn Med. 2021;33(2):196–209.
110.
ZuckermanM, KellyT, HeardK, ZoselA, MarlinM, HoppeJ.Physician attitudes on buprenorphine induction in the emergency department: results from a multistate survey. Clin Toxicol. 2021;59(4):279–285.
111.
ShueyB, LeeD, UgaldeIEvaluation of resident physicians’ knowledge of and attitudes towards prescribing buprenorphine for patients with opioid use disorder. J Addict Med. 2021;15(3):219–225.
112.
CaplehornJR, DaltonMS, HaldarF, PetrenasA-M, NisbetJG.Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31(2):177–196.
113.
KnudsenHK, KnudsenHK, DucharmeLJ, RomanPM.Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine. Am J Addict. 2007;16(5):365–371.
114.
WakemanSE, KanterGP, DonelanK.Institutional substance use disorder intervention improves general internist preparedness, attitudes, and clinical practice. J Addict Med. 2017;11(4):308–314.
